

[illegible]

FOREIGN PATENT DOCUMENTS								
Examiner's Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>8</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
AL			WO 87/05325	PCT		09/11/87		
I			WO 88/03951	PCT		06/02/88		
			WO 88/01648	PCT		03/10/88		
			WO 89/06689	PCT		07/27/89		
			WO 91/04447	PCT		04/01/91		
			WO 91/19810	PCT		12/26/91		
AL			WO 92/06187	PCT		04/16/92		

Examiner's Signature	<i>Deborah Crouch</i>	Date Considered	4/26/00
-------------------------	-----------------------	--------------------	---------

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO					
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/149,718
				Filing Date	September 8, 1998
				First Named Inventor	Kate Dora Games, et al.
				Group Art Unit	1643
				Examiner Name	Not yet assigned
Sheet	Page 2	of	34	Attorney Docket Number	ANS 101 CIP(2)

[illegible]

FOREIGN PATENT DOCUMENTS								
Examiner's Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T*
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
<i>dc</i>			WO 92/13069	PCT		08/06/92		
			WO 93/02189	PCT		02/04/93		
			WO 93/07296	PCT		04/15/93		
			WO 93/14200	PCT		07/22/93		
			WO 94/10569	PCT		05/11/94		
			WO 94/23049	PCT		10/13/94		
<i>dc</i>			WO 95/11968 <i>W 96/8</i>	PCT		05/04/95		

Examiner's Signature	<i>Deborah Cronch</i>	Date Considered	<i>4/26/00</i>
----------------------	-----------------------	-----------------	----------------

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO					
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/149,718
				Filing Date	September 8, 1998
				First Named Inventor	Kate Dora Games, et al.
				Group Art Unit	1643
				Examiner Name	Not yet assigned
				Attorney Docket Number	ANS 101 CIP(2)
Sheet	Page 3	of	34		

[illegible]

FOREIGN PATENT DOCUMENTS								
Examiner's Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
dc			WO 95/11994	PCT		05/04/95		
			WO 95/14769	PCT		06/01/95		
			WO 95/20666	PCT		08/03/95		
			WO 96/13513	PCT		06/07/96		
			WO 96/17926	PCT		06/13/96		
			O 267 678 A1	Europe		05/18/88		
dc			O 279 582 A2	Europe		08/24/88		

Examiner's Signature	<i>Deborah Crook</i>	Date Considered	4/26/00
-------------------------	----------------------	--------------------	---------

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO					
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/149,718
				Filing Date	September 8, 1998
				First Named Inventor	Kate Dora Games, et al.
				Group Art Unit	1643
				Examiner Name	Not yet assigned
Sheet	Page 4	of	34	Attorney Docket Number	ANS 101 CIP(2)

[illegible]

FOREIGN PATENT DOCUMENTS								
Examiner's Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
<i>dc</i>			0 451 700 AT	Europe		10/16/91		
			0 561 087 A1	Europe		09/22/93		
			2 199 845 A	GB		07/20/88		


Examiner's Signature	<i>Deborah Crouch</i>	Date Considered	4/26/00
-------------------------	-----------------------	--------------------	---------

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/149,718
				Filing Date	September 8, 1998
				First Named Inventor	Kate Dora Games, et al.
				Group Art Unit	1643
				Examiner Name	Not yet assigned
Sheet	Page 5	of	34	Attorney Docket Number	ANS 101 CIP(2)

OTHER ART -- NON PATENT LITERATURE DOCUMENTS				
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T <sup>2</sup>	
		Aguzzi, et al., "Transgenic and Knock-out Mice: Models of Neurological Disease,," Brain Pathol. 4:3-20 (1994)		
		Akiyama, et al., "Immunohistochemical localization of vitronectin, its receptor and beta-3 integrin in Alzheimer's brain tissue," J. of Neuroimmunol. 32:19-28 (1991)		
		Akiyama and McGeer, "Brain microglia constitutively express -2 integrins," J. of Neuroimmunol. 30:81-93 (1990)		
		Akiyama, et al., "Morphological diversities of CD44 positive astrocytes in the cerebral cortex of normal subjects and patients with Alzheimer's disease," Brain Res. 632:249-259 (1993)		
		Akiyama, et al., "Expression of the receptor for macrophage colony stimulating factor by brain microglia and its upregulation in brains of patients with Alzheimer's disease and amyotrophic lateral sclerosis," Brain Res. 639:171-174 (1994)		
		Akiyama, et al., "Expression of intercellular adhesion molecule (ICAM)-1 by a subset of astrocytes in Alzheimer's disease and some other degenerative neurological disorders," Acta Neuropathol. 85:628-634 (1993)		
		Akiyama, et al., "Expression of MRP14, 27E10, interferon- and leukocyte common antigen by reactive microglia in postmortem human brain tissue," J. of Neuroimmunol. 50:195-201 (1994)		
		Akiyama, et al., "Microglia express the type2 plasminogen activator inhibitor iini the brain of control subjects and patients with Alzheimer's disease," Neuroscience Letters 164:233-235 (1993)		
		Alberts, A., et al., "Mevinolin: A highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent" Proc. Natl. Acad. Sci. USA 77:3957-3961 (1980)		
		Anderson, et al., "Differential brain expression of the Alzheimer's amyloid precursor protein," EMBO J. 8:3627-3632 (1989)		
dc		Arai et al., "Defined neurofilament, r, and -amyloid precursor protein epitopes distinguish Alzheimer from non-Alzheimer senile plaques," Proc. Natl. Acad. Sci. USA: 87:2249-2253 (1990)		
Examiner's Signature	Deborah Chock		Date Considered	4/26/00


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/149,718
				Filing Date	September 8, 1998
				First Named Inventor	Kate Dora Games, et al.
				Group Art Unit	1643
				Examiner Name	Not yet assigned
Sheet	Page 6	of	34	Attorney Docket Number	ANS 101 CIP(2)

OTHER ART -- NON PATENT LITERATURE DOCUMENTS				
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T <sup>2</sup>	
		Argyle, et al., "Psychogeriatric Patients: Their Supporters' Problems," Age and Ageing 14:355-360 (1985)		
		Araujo and Cotman, "Beta-amyloid stimulates glial cells in vitro to produce growth factors that accumulate in senile plaques in Alzheimer's disease," Brain Research 569:141-145 (1992)		
		Aschoff, "Circadian rhythms: Influences of internal and external factors on the period measured in constant conditions," Zeitschrift fur Tierpsychologie 49:225-249 (1979)		
		Bachmann, S., et al., "Transgenic rats carrying the mouse renin gene--morphological characterization of a low-renin hypertension model" Kidney Int. 41(1):24-36 (1992) (abstract only)		
		Berglund, L., et al., "Effects of lovastatin therapy on guinea pig low density lipoprotein composition and metabolism" J. Lipid Res. 30:1591-1600 (1989)		
		Bick, et al., (Editors) "The early story of Alzheimer's Disease," (Raven Press, New York 1987)		
		Borchelt, D., et al., "Familial Alzheimer's Disease-Linked Presenilin 1 Variants Elevate A 1-42/1-40 Ratio In Vitro and In Vivo" Neuron 17:1005-1013 (1996)		
		Bothwell, et al., "Heavy Chain Variable Region contribution to the NPb Family of Antibodies: Somatic Mutation Evident in a y2a Variable Region," Cell 24:625-637 (1981)		
		Brandan and Inestrosa, "Extracellular matrix components and amyloid in neuritic plaques of Alzheimer's disease," General Pharmacology 24:1063-1068 (1993)		
		Brewer, et al., "Optimized Survival of Hippocampal Neurons in B27-Supplemented NeurobasalTM, a New Serum-free Medium Combination," J. Neuroscience Res. 35(5):567-577 (1993)		
dc		Brown, et al., "Axonal Polypeptides Cross-Reactive with Antibodies to Neurofilament Proteins," Journal of Neurochemistry 40(2): 299-308 (1983)		
Examiner's Signature	Sueverah Cronch		Date Considered	4/26/00

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →


X+

PTO/SB/08A (10-98)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/149,718
				Filing Date	September 8, 1998
				First Named Inventor	Kate Dora Games, et al.
				Group Art Unit	1643
				Examiner Name	Not yet assigned
Sheet	Page 7	of	34	Attorney Docket Number	ANS 101 CIP(2)

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T <sup>2</sup>	
		Burke, et al., "Cloning of Large Segments of Exogenous DNA into Yeast by Means of Artificial Chromosome Vectors," Science 236:806 (1987)		
		Busciglio, J., et al., "Generation of -amyloid in the secretory pathway in neuronal and nonneuronal cells" Proc. Natl. Acad. Sci. USA 90:2092-2096 (1993)		
		Buxbaum, et al. "Calcium Regulates Processing of the Alzheimer Amyloid Protein Precursor in a Protein Kinase C-independent Manner," Proc. Natl. Acad. Sci. USA, 91: 4489-4493 (1994).		
		Buxbaum, et al., "Expression of APP in Brains of Transgenic Mice Containing the Entire Human APP Gene," Biochem. Biophys. Res. Comm. 197:639-645 (1993)		
		Bymaster, et al., "Neurochemical Effects of the M1 Muscarinic Agonist Xanomeline (LY246708/NNC11-0232)," J. Pharm. Exp. Ther. 269:282-289 (1994)		
		Cai, et al., "Release of Excess Amyloid Protein from a Mutant Amyloid Protein Precursor," Science 259:514-516 (1993)		
		Capecchi, "Altering the Genome by Homologous Recombination," Science 244:1288-1292 (1989)		
		Ceballos-Picot, et al., "Neuronal-specific expression of human copper-zinc superoxide dismutase gene in transgenic mice: animal model of gene dosage effects in Down's syndrome," Brain Res. 552:198-214 (1991)		
		Chartier-Harlin, et al., "Early-Onset Alzheimer's Disease Caused by Mutations at Codon 717 of the -Amyloid Precursor Protein Gene," Nature 353: 844-846 (1991)		
		Chomazynski and Sacchi, "Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate-Phenol-chloroform Extraction," Analyt. Biochem. 162:156-159 (1987)		
dc		Chou, et al., "Alzheimer Cortical Neurons Containing Abundant Amyloid mRNA. Relationship to Amyloid Deposition and Senile Plaques," Journal Psychiatric Research 24(1): 37-50 (1990)		
Examiner's Signature	Deborah Crouch		Date Considered	4/26/00

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/149,718
				Filing Date	September 8, 1998
				First Named Inventor	Kate Dora Games, et al.
				Group Art Unit	1643
				Examiner Name	Not yet assigned
Sheet	Page 8	of	34	Attorney Docket Number	ANS 101 CIP(2)

## OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T <sup>2</sup>
dc		Chou, et al., "Alzheimer Cortical Neurons Containing Abundant Amyloid mRNA. Relationship to Amyloid Deposition and Senile Plaques," J. Psych. Res. 24:37-50 (1990)	
		Citron, et al., "Mutation of the -amyloid precursor protein in familial Alzheimer's disease increases -protein production," Nature 360:672-674 (1992)	
		Citron, et al., "Generation of Amyloid Protein from Its Precursor Is Sequence Specific," Neuron 14:661-670 (1995)	
		Connor, "Firms to fight ban on animal patents," New Scientist p. 21 (2/11/88)	
		Corder, "Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families," Science 261:921-923 (1993)	
		Cork, et al., "Neurofibrillary Tangles and Senile Plaques in Aged Bears," J. Neuropath. Exp. Neurol. 47:629-641 (1988)	
		Cowen, "Regulating Biotech: How Much Is Enough?" The Christian Science Monitor p. 16 (June 3, 1988)	
		Cowen, "New Wave Crops Heading for the Farm," The Christian Science Monitor p. 16 (June 1, 1988)	
		Cowen, "'Value Added' Animals: What is On the Horizon?" The Christian Science Monitor p. 16 (June 2, 1988)	
		Coyle, et al., "Alzheimer's Disease: A Disorder of Cortical Cholinergic Innervation," Science 219:1184-1190 (1983)	
dc		David, et al., "Absence of a Close Linkage Between Alzheimer's Disease Susceptibility Gene and a Polymorphic DNA Probe Coding for -Amyloid," Biomedicine & Pharmacotherapy 42:575-578 (1988)	
Examiner's Signature	Deborah Cronch		Date Considered
			7/26/00

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/149,718
		Filing Date	September 8, 1998
		First Named Inventor	Kate Dora Games, et al.
		Group Art Unit	1643
		Examiner Name	Not yet assigned
		Attorney Docket Number	ANS 101 CIP(2)
Sheet	Page 9	of	34

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T <sup>2</sup>
dc		Davies, "Alz-50, A68, and the Paired Helical Filaments of Alzheimer's Disease," The Journal of NIH Research 3:53-56 (1991)	
		Davies and Maloney, "Selective Loss of Central Cholinergic Neurons in Alzheimer's Disease," Lancet 2:1403 (1976)	
		Davies, et al., "Creation of Mice Expressing Human Antibody Light Chains by Introduction of a Yeast Artificial Chromosome Containing the Core Region of the Human Immunoglobulin K Locus," Bio/Technology 11:911-914 (1993)	
		de Boer, J., "Software package for the management of sequencing projects using lacI transgenic animals" Environ. Mol. Mutagenesis 25(3):256-262 (1995) (abstract only)	
		DeFeudis, "Beta-Amyloid Protein in Transgenic Mice," Drug News & Perspectives 4(10):617-619 (1991)	
		Delabar, et al., "Amyloid Gene Duplication in Alzheimer's Disease and Karyotypically Normal Down Syndrome," Science 235:1390-1392 (1987)	
		DeWitt, et al., "Chondroitin Sulfate Proteoglycans Are Associated with the Lesions of Alzheimer's Disease," Exp. Neurol. 121:149-152 (1993)	
		Dickson, et al., "Ubiquitin immunoelectron microscopy of dystrophic neurites in cerebellar senile plaques of Alzheimer's disease," Acta Neuropath. 79:486-493 (1990)	
		Doetschman, et al., "The in vitro development of blastocyst-derived embryonic stem cell lines: formation of visceral yolk sac, blood islands and myocardium," J. Embryol. Exp. Morphol. 87:27 (1985)	
		Dresse, et al., "Towards a Pharmacological Approach of Alzheimer's Disease Based on the molecular Biology of the Amyloid Precursor Protein (APP)," Life Sciences, 55:2179-2187 (1994).	
dc		Duff, et al., "Mouse model made," Nature 373:476-477 (1993)	
Examiner's Signature	Deborah Crand		Date Considered 4/26/00

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/149,718
				Filing Date	September 8, 1998
				First Named Inventor	Kate Dora Games, et al.
				Group Art Unit	1643
				Examiner Name	Not yet assigned
Sheet	Page 10	of	34	Attorney Docket Number	ANS 101 CIP(2)

## OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T <sup>2</sup>	
de		Dugan, et al., "The Ras-related GTP-binding Protein, Rab1B, Regulates Early Steps in Exocytic Transport and Processing of Amyloid Precursor Protein," J. Biological Chem. 270(18):10982-10989 (1995)		
		Dunnett, "Operant delayed matching and non-matching position in rats" in Behavioral Neuroscience, Volume I: A Practical Approach (Sagal, ed., IRL Press, N.Y., 1993) pages 123-136		
		Ebert, K., et al., "A Moloney MLV-rat somatotropin fusion gene produces biologically active somatotropin in a transgenic pig" Mol. Endocrinol. 2(3):277-283 (1988) (abstract only)		
		Ennaceur and Delacour, "A new one-trial for neurobiological studies of memory in rats. 1. Behavioral data," Behav. Brain Res. 31:47-59 (1988)		
		Epstein, et al., "Transgenic mice with increased Cu/Zn-superoxide dismutase activity: Animal model of dosage effects in Down syndrome," Proc. Natl. Acad. Sci. USA 84:8044-8048 (1987)		
		Esch, et al., "Cleavage of amyloid peptide during constitutive processing of its precursor," Science 248:1122-1124 (1991)		
		Estus, et al., "Potentially amyloidogenic, carboxyl-terminal derivatives of the amyloid protein precursor," Science 255:726-728 (1992)		
		Estus, et al., "Altered Gene Expression in Neurons during Programmed Cell Death: Identification of c-jun as Necessary for Neuronal Apoptosis," J. Cell Biol. 127:1717-1727 (1994)		
		Felsenstein et al., "Transgenic Rat and In-Vitro Studies of beta-amyloid Precursor Protein Processing" in Alzheimer's and Parkinson's Diseases (Hanin, ed., Plenum Press, New York, 1995), pages 401-409		
		First, N., "New animal breeding techniques and their application" J. Reprod. Fertil. Suppl. 41:3-14 (1990) (abstract only)		
de		Fisher, "Start-Ups Join Alzheimer Race," New York Times, August 23, 1989 D1		
Examiner's Signature	Deborah Cox		Date Considered	4/26/00

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →


X+

PTO/SB/08A (10-98)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/149,718
				Filing Date	September 8, 1998
				First Named Inventor	Kate Dora Games, et al.
				Group Art Unit	1643
				Examiner Name	Not yet assigned
Sheet	Page 11	of	34	Attorney Docket Number	ANS 101 CIP(2)

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T <sup>2</sup>	
		Flood et al., "Amnestic effects in mice of four synthetic peptides homologous to amyloid protein from patients with Alzheimer disease," Proc. Natl. Acad. Sci. 88:3363-3366 (1986)		
		Frederickson and Brunden, "New Opportunities in AD Research - Roles of Immunoinflammatory Responses and Glia," Alzheimer Disease and Associated Disorders 8:159-165 (1994)		
		Freeman and Bumstead, "Transgenic poultry: theory and practice," World's Poultry Science Journal 43:180-189 (1987)		
		Fukuchi, et al., "Transgenic Animal Models for Alzheimer's Disease," Ann. N.Y. Acad. Sci. 695:217-223 (1993)		
		Fukuchi, et al., "Overexpression of amyloid precursor protein alters its normal processing and is associated with neurotoxicity," Biophys. Res. Commun. 182:165-173 (1992)		
		Fukuchi, et al., "Expression of a carboxy-terminal region of the B-amyloid precursor protein in a heterogenous culture of neuroblastoma cells: evidence for altered processing and selective neurotoxicity," Mol. Brain Res. 16:37-46 (1992)		
		Furuya, et al., "Amyloid -Protein Gene Duplication is not Common in Alzheimer's Disease: Analysis by Polymorphic Restriction Fragments," Biochemical and Biophysical Research Communications 150(1):75-81 (1988)		
		Gabuzda, et al. "Inhibitor of B-Amyloid Production by Activation of Protein Kinase C," J. Neurochemistry, 61: 2326-2329 (1993).		
		Games, et al., "Lack of Alzheimer Pathology After -Amyloid Protein Injections in Rat Brain," Neurobiol. Aging 13:569-576 (1992)		
		Games, et al., "Alzheimer-type neuropathology in transgenic mice overexpressing V717F -amyloid precursor protein," Nature 373:523-527 (1995)		
dc		Ganten, D., et al., "Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes" Proc. Natl. Acad. Sci. USA 89(16):7806-7810 (1992) (abstract only)		
Examiner's Signature	Deborah Cronch		Date Considered	4/26/00

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/149,718
				Filing Date	September 8, 1998
				First Named Inventor	Kate Dora Games, et al.
				Group Art Unit	1643
				Examiner Name	Not yet assigned
Sheet	Page 12	of	34	Attorney Docket Number	ANS 101 CIP(2)

## OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T <sup>3</sup>
de		Garfield, et al., "Differential Effects of Ketamine Stereoisomers on Maze Performance in the Mouse," Anesthesiology 63:681-683 (1985)	
		Glanville, et al., "Structure of Mouse Metallothionein-I Gene and its mRNA," Nature 292:267-269 (1981)	
		Glenner, et al., "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," Biochemical and Biophysical Research Communications 120(3):885-890 (1984)	
		Goate, et al., "Segregation of a Missense Mutation in the Amyloid Precursor Protein Gene with Familial Alzheimer's Disease," Nature 349:704-706 (1991)	
		Golde, et al., "Expression of Amyloid Protein Precursor mRNAs: Recognition of a Novel Alternatively Spliced Form and Quantitation in Alzheimer's Disease Using PCR," Neuron 4:253-267 (1990)	
		Golde, et al., "Processing of the amyloid protein precursor to potentially amyloidogenic derivatives," Science 255:728-730 (1992)	
		Goldgaber, et al., "Characterization and Chromosomal Localization of a cDNA Encoding Brain Amyloid of Alzheimer's Disease," Science 235:877-880 (1987)	
		Gravina, et al., "Amyloid Protein (A) in Alzheimer's Disease Brain," J. Biol. Chem. 270:7013-7016 (1995)	
		Greenamyre and Maragos, "Neurotransmitter Receptors in Alzheimer Disease," Cerebrovascular and Brain Metabolism Reviews 5:61-94 (1993)	
		Greenberg, et al., "APP Transgenesis: Approaches Toward the Development of Animal Models for Alzheimer Disease Neuropathology", <u>Neurobiology of Aging</u> , 17(2):153-171 (1996).	
dc		Griffith and Griffith (Editors) "Mutagenesis by PCR" in PCR Technology: Current Innovations (CRC Press, 1994) pages 69-83	
Examiner's Signature	Deborah Crook		Date Considered
		4/26/00	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/149,718
				Filing Date	September 8, 1998
				First Named Inventor	Kate Dora Games, et al.
				Group Art Unit	1643
				Examiner Name	Not yet assigned
Sheet	Page 13	of	34	Attorney Docket Number	ANS 101 CIP(2)

### OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T <sup>2</sup>
dc		Haass, et al. "Polarized Secretion of B-Amyloid Precursor Protein and Amyloid β- Peptide in MDCK Cells," Proc. Natl. Acad. Sci. USA, 91: 1564-1568 (1995).	
		Haass and Selkoe, "Cellular Processing of -Amyloid Precursor Protein and the Genesis of Amyloid -Peptide," Cell 75:1039-1042 (1993)	
		Hammer, R., et al., "Production of transgenic rabbits, sheep and pigs by microinjection" Nature 315(6021):680-683 (1985) (abstract only)	
		Hammer, R., et al., "Genetic engineering of mammalian embryos" J. Anim. Sci 63(1):269-278 (1986) (abstract only)	
		Hammer, et al., "Spontaneous Inflammatory Disease in Transgenic Rats Expressing HLA-B27 and Human 2m: An Animal Model of HLA-B27-Associated Human Disorders," Cell 63:1099-1112 (1990)	
		Hansen, et al., "Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill," J. Immun. Method. 119:203-210 (1989)	
		Hardy, J., "Amyloid, the presenilins and Alzheimer's disease" Trends in Neuroscience 20(4):154-159 (1997)	
		Hardy, "Framing -amyloid," Nature Genetics 1:233-234 (1992)	
		Hardy and Allsop, "Amyloid deposition as the central event in the aetiology of Alzheimer's disease," Trends in Pharm. Sci. 12:383-388 (1991)	
		Harlow et al., Antibodies: A Laboratory Manual (Cold Spring Harbor, NY 1988)	
dc		He, et al., "Expression of a large family of POU-domain regulatory genes in mammalian brain development," Nature 340:35-42 (1989)	
Examiner's Signature	Deborah Cronch		Date Considered
			4/26/00

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/149,718
				Filing Date	September 8, 1998
				First Named Inventor	Kate Dora Games, et al.
				Group Art Unit	1643
				Examiner Name	Not yet assigned
				Attorney Docket Number	ANS 101 CIP(2)
Sheet	Page 14	of	34		

## OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T <sup>2</sup>	
		Hendriks, et al., "Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the -amyloid precursor protein gene," Nature Genetics 1:218-221 (1992)		
		Higgins, et al. "Transgenic Mice Expressing Human -APP751, But Not Mice Expressing -APP695, Display Early Alzheimers Disease-like Histopathology" Ann. N.Y Acad. Sci. 695: 224-227 (1993).		
		Higgins, et al., "Transgenic Mouse Brain Histopathology Resembles Early Alzheimer Disease," Ann Neurol. 35:598-607 (1995)		
		Higgins, et al. "Genetically Engineered Animal Models of Human Neurodegenerative Diseases," Neurodegeneration, 4: 117-129 (1995).		
		Higgins, L., et al., "Genetically Engineered Animal Models of Alzheimer's Disease" METHODS: A Companion to Methods in Enzymology 10:384-391 (1996)		
		Higgins, et al., "Early Alzheimer disease-like histopathology increases in frequency with age in mice transgenic for -APP751," Proc. Natl. Acad. Sci. USA 92:4402-4406 (1995)		
		Himber, J., et al., "Effects of stigmastanyl-phosphocholine (Ro 16-6532) and lovastatin on lipid and lipoprotein levels and lipoprotein metabolism in the hamster on different diets" J. Lipid Res. 36:1567-1585 (1995)		
		Hogan, et al., Manipulating the Mouse Embryo (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1986)		
		Howland, et al., "Mutant and Native Human -Amyloid Precursor Proteins in Transgenic Mouse Brain" Neurobiol. of Aging 16:685-699 (1995)		
		Hsiao, "Age related CNS Disorder and Early Death in Transgenic FVB/N Mice Overexpressing Alzheimer Amyloid Precursor Proteins" Neuron, 15: 1203-1218 (1995).		
dc		Hsiao, K., et al., "Correlative Memory Deficits, A Elevation, and Amyloid Plaques in Transgenic Mice" Science 274:99-102 (1996)		
Examiner's Signature	Deborah Crook		Date Considered	4/26/00

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/149,718
		Filing Date	September 8, 1998
		First Named Inventor	Kate Dora Games, et al.
		Group Art Unit	1643
		Examiner Name	Not yet assigned
		Attorney Docket Number	ANS 101 CIP(2)
Sheet	Page 15	of	34

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T <sup>2</sup>
dc		Huang, et al., "Intervening sequences increase efficiency of RNA 3' processing and accumulation of cytoplasmic RNA," Nucleic Acids Res. 18:937-947 (1990)	
		Huff, M., et al., "Regulation of Low Density Lipoprotein Apoprotein B Metabolism by Lovastatin and Cholestyramine in Miniature Pigs: Effects on LDL Composition and Synthesis of LDL Subfractions" Metabolism 38(3):256-264 (1989)	
		Hung, et al., "Activation of Protein Kinase C Inhibits Cellular Production of the Amyloid -Protein," J. Biol. Chem. 268:22959-22962 (1993)	
		Hyman, et al., "Amyloid, dementia, and Alzheimer's disease," Current Opinion in Neurology and Neurosurgery, 5:88-93 (1992)	
		Jenkins, et al., "Fine Mapping of an Alzheimer Disease-Associated Gene Encoding Beta-Amyloid Protein," Biochemical and Biophysical Research Communications 151(1):1-8 (1988)	
		Joachim, et al. "The Seminal Role of $\beta$ -Amyloid in the Pathogenesis of Alzheimer Disease," <i>Alzheimer's Disease and Associated Disorders</i> , 6:7-34 (1992).	
		Joachim, et al., "Amyloid -Protein Deposition in Tissues Other than Brain in Alzheimer's Disease," Nature 341:226-230 (1989)	
		Jorm (Editors) A Guide to the Understanding of Alzheimer's Disease and Related Disorders, (New York University Press, New York 1987)	
		Joyner, et al., "Production of a mutation in mouse En-2 gene by homologous recombination in embryonic stem cells," Nature 338:153-156 (1989)	
		Jucker, et al., "Age-associated inclusions in normal and transgenic mouse brain," Science 255:1443-1445 (1992) :	
dc		Kalaria and Perry, "Amyloid P component and other acute-phase proteins associated with cerebellar A -deposits in Alzheimer's disease," Brain Research 631:151-155 (1993)	
Examiner's Signature	Deborah Cronch		Date Considered 4/26/00

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/149,718
				Filing Date	September 8, 1998
				First Named Inventor	Kate Dora Games, et al.
				Group Art Unit	1643
				Examiner Name	Not yet assigned
Sheet	Page 16	of	34	Attorney Docket Number	ANS 101 CIP(2)

## OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T <sup>2</sup>	
dc		Kammesheidt, et al., "Deposition of /A4 immunoreactivity and neuronal pathology in transgenic mice expressing the carboxy-terminal fragment of the Alzheimer amyloid precursor in the brain," Proc. Natl. Acad. Sci. USA 89:10857-10861 (1992)		
		Kang, et al., "The Precursor of Alzheimer's Disease Amyloid A4 Protein Resembles a Cell-Surface Receptor," Nature 325:733-736 (1987)		
		Kasof, G., et al., "Developmental expression of Fos-lacZ in the brains of postnatal transgenic rats" Brain Research. Developmental Brain Research 93(1-2):191-197 (1996) (abstract only)		
		Katzman, "Alzheimer's Disease," The New England Journal of Medicine 314(15): 964-973 (1986)		
		Kawabata, et al., "Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein," Nature 356:265 (1992)		
		Kawabata, et al., "Alzheimer's Retraction," Nature 356:23 (1992)		
		Kawabata, et al., "Amyloid Plaques, Neurofibrillary Tangles and Neuronal Loss in Brains of Transgenic Mice Overexpressing a C-Terminal Fragment of Human Amyloid Precursor Protein," Nature 354: 476-478 (1991)		
		Kawamata, et al., "Lactotransferrin Immunocytochemistry in Alzheimer and Normal Human Brain," Am. J. of Pathol. 142:1574-1585 (1993)		
		Kelly (Editors) Alzheimer's Disease and Related Disorders, Research and Development (Charles C. Thomas, Springfield, IL. 1984)		
		Kidd, "Paired Helical Filaments in Electron Microscopy of Alzheimer's Disease," Nature 197:192-193 (1963)		
dc		Kesner, et al., "Medial Septal and Nucleus Basalis Magnocellularis Lesions Produce Order Memory Deficits in Rats Which Mimic Symptomatology of Alzheimer's Disease," Neurobiol. Aging 7:287-292 (1986)		
Examiner's Signature	Deborah Cox		Date Considered	4/26/00

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/149,718
				Filing Date	September 8, 1998
				First Named Inventor	Kate Dora Games, et al.
				Group Art Unit	1643
				Examiner Name	Not yet assigned
Sheet	Page 17	of	34	Attorney Docket Number	ANS 101 CIP(2)

## OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T <sup>2</sup>	
dc		Kitaguchi, et al., "Novel Precursor of Alzheimer's Disease Amyloid Protein Shows Protease Inhibitory Activity," Nature 331:530-532 (1988)		
		Knops, et al., "Isolation of Baculovirus-derived Secreted and Full-length -Amyloid Precursor Protein," J. of Biol. Chem. 266:7285-7290 (1991)		
		Kosik, et al., "Alzheimer's Disease: A Cell Biological Perspective," Science 256:780-783 (1992)		
		Kowall, et al., "An In Vivo Model for the Neurodegenerative Effects of Amyloid and Protection by Substance P," Proceedings of the National Academy of Science (U.S.A.) 88:7247-7251 (1991)		
		Kovanen, P., et al., "Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog" Proc. Natl. Acad. Sci. USA 78:1194-1198 (1981)		
		Lamb, et al. "Introduction and Expression of the 400 Kilobase Precursor Amyloid Protein Gene in Transgenic Mice," Nature Genetics, 5:22-30 (1993).		
		Lannfelt, et al., "Alzheimer's disease: molecular genetics and transgenic animal models," Behavioural Brain Res. 57:207-213 (1993)		
		La Ville, A., et al., "Inhibition of cholesterol synthesis reduces low-density-lipoprotein apoprotein B production without decreasing very-low-density-lipoprotein apoprotein B synthesis in rabbits" Biochem. J. 219:321-323 (1984)		
		Lee, "Unraveling the Mystery of the Paired Helical Filaments of Alzheimer's Disease," The Journal of NIH Research 3:52-55 (1991)		
		Lees-Miller, et al., "Three Novel Brain Tropomyosin Isoforms Are Expressed from the Rat -Tropomyosin Gene through the Use of Alternative Promoters and Alternative RNA Processing," Mol. Cell. Biol. 10(4):1729-1742 (1990)		
	dc		Lemaire, et al., "The PreA4695 Precursor Protein of Alzheimer's Disease A4 Amyloid is Encoded by 16 Exons," Nucleic Acids Research 17(2):517-522 (1989)	
Examiner's Signature	Deborah Cronch		Date Considered	4/26/00

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/149,718
		Filing Date	September 8, 1998
		First Named Inventor	Kate Dora Games, et al.
		Group Art Unit	1643
		Examiner Name	Not yet assigned
Sheet	Page 18	of	34
		Attorney Docket Number	ANS 101 CIP(2)

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T <sup>2</sup>
dc		Leveugle and Fillif, "Proteoglycans and the Acute-Phase Response in Alzheimer's Disease Brain," Molecular Neurobiol. 9:25-32 (1994)	
		Levy, et al., "Mutation of the Alzheimer's Disease Amyloid Gene in Hereditary Cerebral Hemorrhage, Dutch Type," Science 248:1124-1126 (1990)	
		List of Presentations on APP and A, Cambridge Healthtech Institute's Second Conference on Alzheimer's Disease (1997)	
		List of Presentations on APP and A, IBC's 6th Annual Conference on Alzheimer's Disease (1997)	
		Lo, D., et al., "Expression of mouse IgA by transgenic mice, pigs and sheep" Eur. J. Immunol. 21(4):1001-1006 (1991) (abstract only)	
		Lo, et al. "Metabolism of the "Swedish" Amyloid Precursor Protein Variant in Madin-Darby Canine Kidney Cells," J. Biol. Chem. 269:30966-30973 (1994).	
		Lovell-Badge, Teratocarcinomas and Embryonic Stem Cells, A Practical Approach, (Robertson, E.J., Editors, IRL Press 1987)	
		Lovestone and Anderton, "Cytoskeletal abnormalities in Alzheimer's disease," Current Opinion in Neurology and Neurosurgery 5:883-888 (1992)	
		Maggio, J., et al., "Reversible in vitro growth of Alzheimer disease -amyloid plaques by deposition of labeled amyloid peptide" Proc. Natl. Acad. Sci. U.S.A. 89:5462-5466 (1992)	
		Majocha, et al., "Monoclonal Antibody to Embryonic CNS Antigen A2B5 Provides Evidence for the Involvement of Membrane Components at Sites of Alzheimer Degeneration and Detects Sulfatides as Well as Gangliosides," Journal of Neurochemistry 53(3):953-961 (1989)	
dc		Majocha, et al., "Immunostaining of Neurofilament Protein in Human Postmortem Cortex: A Sensitive and Specific Approach to the Pattern Analysis of Human Cortical Cytoarchitecture," Canadian Journal of Biochemistry and Cell Biology 63:577-584 (1985)	
Examiner's Signature	Deborah Cronch		Date Considered 4/26/00

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/149,718
				Filing Date	September 8, 1998
				First Named Inventor	Kate Dora Games, et al.
				Group Art Unit	1643
				Examiner Name	Not yet assigned
Sheet	Page 19	of	34	Attorney Docket Number	ANS 101 CIP(2)

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T <sup>2</sup>
dc		Mann, et al., "Cerebral Amyloidosis, Ageing and Alzheimer's Disease; A contribution From Studies on Down's Syndrome," Neurobiol. Aging 10:397-399 (1989)	
		Manning, et al., "Identification in Rodents and other Species of an mRNA Homologous to the Human -Amyloid Precursor," Molecular Brain Research 3:293-298 (1988)	
		Mansour, et al., "Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes," Nature 336:348-352 (1988)	
		Marotta, et al., "Overexpression of Amyloid Precursor Protein A4 (-Amyloid) Immunoreactivity in Genetically Transformed Cells: Implications for a Cellular Model of Alzheimer Amyloidosis," Proceedings of the National Academy of Science (U.S.A.) 86:337-341 (1989)	
		Martin, et al., "Intracellular Accumulation of $\beta$ -Amyloid in Cells expressing the swedish Mutant amyloid Precursor Protein," J. Biol. Chem. 270:26727-26730 (1994).	
		Martin, et al., "Amyloid Precursor Protein in Aged Nonhuman Primates," Proceedings of the National Academy of Science (U.S.A.) 88:1461-1465 (1991)	
		Maruyama, et al., "Formation of Amyloid-Like Fibrils in COS Cells Overexpressing Part of the Alzheimer Amyloid Protein Precursor," Nature 347:566-569 (1990)	
		Marx, "Alzheimer's Research Moves to Mice," Science 253:266-267 (1991)	
		Marx, "Mutation Identified as a Possible Cause of Alzheimer's Disease," Science 251:876-877 (1991)	
		Marx, "Major Setback for Alzheimer's Models," Science 255:1200-1202 (1992)	
dc		Masliah, et al., "An Antibody Against Phosphorylated Neurofilaments Identifies a Subset of Damaged Association Axons in Alzheimer's Disease," American Journal of Pathology 142:871-882 (1993)	
Examiner's Signature	Deborah Croxall		Date Considered
			4/26/00

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/149,718
				Filing Date	September 8, 1998
				First Named Inventor	Kate Dora Games, et al.
				Group Art Unit	1643
				Examiner Name	Not yet assigned
Sheet	Page 20	of	34	Attorney Docket Number	ANS 101 CIP(2)

## OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T <sup>2</sup>
dc		Masliah, et al., "Cortical and Subcortical Patterns of Synaptophysinlike Immunoreactivity in Alzheimer's Disease," Am. J. Path. 138:235-246 (1991)	
		Masliah, et al., "Localization of amyloid precursor protein in GAP43-immunoreactive aberrant sprouting neurites in Alzheimer's disease," Brain Research 574:312-316 (1992)	
		Masliah, et al., "Immunoelectron microscopic study of synaptic pathology in Alzheimer's disease," Acta Neuropath. 81:428-433 (1991)	
		Masliah and Terry, "Role of Synaptic Pathology in the Mechanisms of Dementia in Alzheimer's Disease," Clinical Neuroscience 1:192-198 (1993)	
		Masliah, et al., "Re-Evaluation of the Structural Organization of Neuritic Plaques in Alzheimer's Disease," J. Neuropath. Exp Neurol. 52:619-632 (1993)	
		Masters, et al., "Amyloid Plaque Core Protein in Alzheimer Disease and Down Syndrome," Proceedings of the National Academy of Science (U.S.A.) 82:4245-4249 (1985)	
		Matsunaga, A., et al., "Effect of simvastatin on receptor mediated metabolism of low density lipoprotein in guinea pigs" Atherosclerosis 90:31-37 (1991)	
		Maue, et al., "Neuron-Specific Expression of the Rat Brain Type II Sodium Channel Gene Is Directed by Upstream Regulatory Elements," Neuron 4:223-231 (1990)	
		McConlogue, et al., "Transgenic Mice Expressing Human Alzheimer's -Amyloid Precursors Protein Produce High Amounts of -Peptide," Neurobiol. Aging 15:S1 Abstract 49 (1994)	
		McDonald and Nemeroff, "Neurotransmitters and Neuropeptides in Alzheimer's Disease," Psychiatric Clinics of North America 14:421-422 (1991)	
dc		McDuff and Sumi, "Subcortical degeneration in Alzheimer's disease," Neurobiol. 35:123-126 (1985)	
Examiner's Signature	Deborah Crand		Date Considered
			4/26/00

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/149,718
				Filing Date	September 8, 1998
				First Named Inventor	Kate Dora Games, et al.
				Group Art Unit	1643
				Examiner Name	Not yet assigned
Sheet	Page 21	of	34	Attorney Docket Number	ANS 101 CIP(2)

## OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T <sup>2</sup>
dc		McGeer, et al., "Reactions of the Immune System in Chronic Degenerative Neurological Diseases," Canadian Journal of Neurological Sciences 18:376-379 (1991)	
		McGeer, et al., "Distribution of clusterin in Alzheimer brain tissue," Brain Res. 579:337-341 (1992)	
		McGeer, et al., "Immune System Response in Alzheimer's Disease," Canadian Journal of Neurological Sciences 16:516-527 (1989)	
		McGeer, et al., "Detection of the membrane inhibitor of reactive lysis (CD59) in diseased neurons of Alzheimer brain," Brain Res. 544:315-319 (1991)	
		McLean, I., et al., "Periodate-Lysine-Paraformaldehyde Fixative A New Fixative for Immunoelectron Microscopy" J. Histochem. Cytochem. 22(12):1077-1083 (1974)	
		Meena-Leist and Parker, "Amyloid Deposition in Alzheimer's Disease," Ann. di. Lab. Sci., 23:173-177 (1993)	
		Miller, et al., "Peptide Compositions of the Cerebrovascular and Senile Plaque Core Amyloid Deposits of Alzheimer's Disease," Archives Biochem. Biophys. 301(1):41-52 (1993)	
		Mistry, et al., "Neurochemistry of Aging. 1. Toxins for an Animal Model of Alzheimer's Disease," J Med Chem 29:376-380 (1986)	
		Mohr, et al., "Neurotransmitter Replacement Therapy in Alzheimer's Disease," Journal of Psychiatry & Neuroscience 19:17-23 (1994)	
		Moran, et al. "Age-Related Learning Deficits in Transgenic Mice Expressing the 751-Amino Acid Isoform of Human $\beta$ -Amyloid Precursor Protein," Proc. Natl. Acad. Sci. USA, 92: 5341-5345 (1995).	
dc		Morris, "Spatial Localization Does Not Require the Presence of Local Cues," Learn Motiv. 12:239-260 (1981)	
Examiner's Signature	Deborah Cronk		Date Considered
			4/26/00

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/149,718
				Filing Date	September 8, 1998
				First Named Inventor	Kate Dora Games, et al.
				Group Art Unit	1643
				Examiner Name	Not yet assigned
Sheet	Page 22	of	34	Attorney Docket Number	ANS 101 CIP(2)

## OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T <sup>2</sup>
dc		Mucke, et al., "Synaptotrophic effects of human amyloid B protein precursors in the cortex of transgenic mice," Brain Res. 666:151-167 (1994)	
		Mullan, et al., "A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of -amyloid," Nature Genet. 1:345-347 (1992)	
		Muller, et al. "Behavioral and Anatomical Deficits in Mice Homozygous for a Modified B -Amyloid Precursor Protein Gene," Cell 79: 755-765 (1994).	
		Mullins, J., et al., "Transgenesis in Nonmurine Species" Hypertension 22:630-633 (1993)	
		Mullis and Faloona, "Specific Synthesis of DNA in Vitro via a Polymerase-Catalyzed Chain Reaction," Methods Enzymol. 155:335-350 (1987)	
		Murray, J., et al., "Production of transgenic merino sheep by microinjection of ovine metallothionein-ovine growth hormone fusion genes" Reprod. Fertil. Dev. 1(2):147-155 (1989) (abstract only)	
		Murrell, et al., "A Mutation in the Amyloid Precursor Protein Associated with Hereditary Alzheimer's Disease," Science 254:97-99 (1991)	
		Nitsch, et al., "Release of Alzheimer Amyloid Precursor Derivatives Stimulated by Activation of Muscarinic Acetylcholine Receptors," Science 258:304-307 (1992)	
		Nitsch, et al., Proceedings of the Eighth Meeting of the International Study Group on the Pharmacology of Memory Disorders Associated with Aging, Zurich, Switzerland 204-212 (1995)	
		Oltersdorf, et al., "The Alzheimer Amyloid Precursor Protein," J. Biol. Chem. 265:4492-4497 (1990)	
dc		Olton and Samuelson, "Animal Behavior Processes," J. Exp. Psychol. 2:97-116 (1976)	
Examiner's Signature	Deborah Cronch		Date Considered
			4/26/00

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

X+

PTO/SB/08A (10-98)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/149,718
				Filing Date	September 8, 1998
				First Named Inventor	Kate Dora Games, et al.
				Group Art Unit	1643
				Examiner Name	Not yet assigned
Sheet	Page 23	of	34	Attorney Docket Number	ANS 101 CIP(2)

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T <sup>2</sup>	
de		Palmiter, et al., "Dramatic growth of mice that develop from eggs microinjected with metallothionein-growth hormone fusion genes," Nature 300:611 (1982)		
		Palmiter, "Germ-Like Transformation of Mice," Annual Review of Genetics 20:465-499 (1986)		
		Patterson et al., "Mapping of the Gene Encoding the -Amyloid Precursor Protein and its Relationship to the Down Syndrome Region of Chromosome 21," Proceedings of the National Academy of Science (U.S.A.) 85: 8266-8270 (1988)		
		Pearson and Choi, "Expression of the human -amyloid precursor protein gene from a yeast artificial chromosome in transgenic mice," Proc. Natl. Acad. Sci. USA 90:10578-10582 (1993)		
		Pericak-Vance, et al., "Genetic Linkage Studies in Alzheimer's Disease Families," Experimental Neurology 102:271-279 (1988)		
		Perry, et al., "Necropsy Evidence of Central Cholinergic Deficits in Senile Dementia," Lancet 1:189 (1977)		
		Perry, "The cholinergic hypothesis - ten years on," British Medical Bulletin 42:63-69 (1986)		
		Pittendrigh, et al., "A functional analysis of circadian pacemaker in nocturnal rodents," J. of Comparative Physiol. 106:291-331 (1976)		
		Podlisny, et al., "Gene Dosage of the Amyloid Precursor Protein in Alzheimer's Disease," Science 238:669-671 (1987)		
		Podlisny, et al., "Synthetic Amyloid -Protein Fails to Produce Specific Neurotoxicity in Monkey cerebral Cortex" Neurobiology of Aging 13: 561-567 (1992).		
de		Ponte, et al., "A New A4 Amyloid mRNA Contains a Domain Homologous to Serine Proteinase Inhibitors," Nature 331:525-527 (1988)		
Examiner's Signature	Deborah Crand		Date Considered	4/26/00

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/149,718
				Filing Date	September 8, 1998
				First Named Inventor	Kate Dora Games, et al.
				Group Art Unit	1643
				Examiner Name	Not yet assigned
Sheet	Page 24	of	34	Attorney Docket Number	ANS 101 CIP(2)

## OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T <sup>2</sup>
dc		Popko, et al., "Myelin Deficient Mice: Expression of Myelin Basic Protein and Generation of Mice with Varying Levels of Myelin," Cell 48:713-721 (1987)	
		Potempska, et al., "Purification and Tissue Level of the -Amyloid Peptide Precursor of Rat Brain," J. of Biol. Chem. 266:8464-8469 (1991)	
		Potter, et al., "Enhancer-dependent expression of human K immunoglobulin genes introduced into mouse pre-B lymphocytes by electroporation," Proc. Natl. Acad. Sci. USA 81:7161 (1984)	
		Price, et al., "Alzheimer's Disease and Down's Syndrome," Annals of the New York Academy of Sciences 145-164 (1982)	
		Price, et al., "Alzheimer disease and the prion disorders amyloid -protein and prion protein amyloidoses," Proc. Natl. Acad. Sci. USA 90:6381-6384 (1993)	
		Price, et al., "Cellular and Molecular Biology of Alzheimer's Disease," BioAssays 10(2&3):69-74 (1989)	
		Price, et al., "Amyloidosis in aging and Alzheimer's disease," Am. J. Pathol. 141:767-772 (1992)	
		Prinz, et al., "Sleep, EEG and Mental Function Changes in Senile Dementia of the Alzheimer's Type," Neurobiol. Aging 3:361-370 (1982)	
		Pursel, V., et al., "Integration, expression and germ-line transmission of growth-related genes in pigs" J. Reprod. Fertil. Suppl. 41:77-87 (1990) (abstract only)	
		Pursel, V., et al., "Expression and performance in transgenic pigs" J. Reprod. Fertil. Suppl. 40:235-245 (1990) (abstract only)	
dc		Pursel, V., et al., "Progress on gene transfer in farm animals" Vet. Immunol. Immunopathol. 17(1-4):303-312 (1987) (abstract only)	
Examiner's Signature	Deborah Cronch		Date Considered
		4/26/00	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box →



PTO/SB/08A (10-98)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/149,718
		Filing Date	September 8, 1998
		First Named Inventor	Kate Dora Games, et al.
		Group Art Unit	1643
		Examiner Name	Not yet assigned
Sheet	Page 25	of	34
		Attorney Docket Number	ANS 101 CIP(2)

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T <sup>2</sup>
dc		Pursel, V., et al., "Genetic engineering of livestock" Science 244(4910):1281-1288 (1989) (abstract only)	
		Qiagen, Inc., (Publishers) The Qiagenologist, Application Protocols, 3rd edition, Chatsworth, CA.	
		Quon, et al., "Formation of -Amyloid Protein Deposits in Brains of Transgenic Mice," Nature 352:239-241 (1991)	
		Ray, et al., "Ectopic expression of a c-kitw42 minigene in transgenic mice: recapitulation of W phenotypes and evidence for c-kit function in melanoblast progenitors," Genes and Development 5:2265-2273 (1991)	
		Readhead, et al., "Expression of a Myelin Basic Protein Gene in Transgenic Shiverer Mice: Correction of the Dysmyelinating Phenotype," Cell 48:703-712 (1987)	
		Reddy, et al., "The Genome of Simian Virus 40," Science 200:494-502 (1978)	
		Reisberg, "Alzheimer's Disease," (Editors, The Free Press, New York & London) (1993)	
		Rexroad, C., et al., "Insertion, expression and physiology of growth-regulating genes in ruminants" J. Reprod. Fertil. Suppl. 41:119-124 (1990) (abstract only)	
		Rexroad, C., et al., "Production of transgenic sheep with growth-regulating genes" Mol. Reprod. Dev. 1(3):164-169 (1989) (abstract only).	
		Rexroad, C., et al., "Transferrin- and albumin-directed expression of growth-related peptides in transgenic sheep" J. Anim. Sci. 69(7):2995-3004 (1991) (abstract only)	
dc		Robakis, et al., "Molecular Cloning and Characterization of a cDNA Encoding the Cerebrovascular and the Neuritic Plaque Amyloid Peptides," Proceedings of the National Academy of Science (U.S.A.) 84:4190-4194 (1987)	
Examiner's Signature	Deborah Cronch		Date Considered
			4/26/00

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/149,718
				Filing Date	September 8, 1998
				First Named Inventor	Kate Dora Games, et al.
				Group Art Unit	1643
				Examiner Name	Not yet assigned
Sheet	Page 26	of	34	Attorney Docket Number	ANS 101 CIP(2)

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T <sup>2</sup>
dc		Rockenstein, et al. "Levels and Alternate Splicing of Amyloid & Protein Precursor (APP) Transcripts in Brains of APP Transgenic Mice and Humans with Alzheimer's Disease," J. Bio. Chemistry 270(47):28257-28267 (1994).	
		Rodríguez-Echenique, C., et al., "Effects of Policosanol Chronically Administered in Male Monkeys (MACACA ARCTOIDES)" Ed. Chem. Toxic. 32(6):565-575 (1994)	
		Rumble, et al., "Amyloid A4 Protein and Its Precursor in Down's Syndrome and Alzheimer's Disease," New England J. Med. 320:1446-1452 (1989)	
		Rylett, et al., "Evidence for High Affinity Choline Transport in Synaptosomes Prepared from Hippocampus and Neocortex of Patients with Alzheimer's Disease," Brain Res 289:169-175 (1983)	
		Saido, et al., "Spatial Resolution of the Primary -Amyloidogenic Process Induced in Postischemic Hippocampus," J. Biol. Chem. 269:15253-15257 (1994)	
		Saitoh, et al., "Secreted Form of Amyloid Protein Precursor is Involved in the Growth Regulation of Fibroblasts," Cell 58:615-622 (1989)	
		Sajdel-Sulkowska, "RNA Synthesis in the Nondemented and Alzheimer's Disease Postmortem Brain," J. Neuropathol. Exp. Neurol. 48:327 (1989)	
		Sakimura, et al., "Partial Purification and Characterization of Messenger RNA Coding 14-3-2 Protein from Rat Brain," Journal of Neurochemistry 39(2):366-370 (1982)	
		Sakimura, et al., "The structure and expression of neuron-specific enolase gene," Gene 60:103-113 (1987)	
		Salbaum, et al., "The promoter of Alzheimer's disease amyloid A4 precursor gene," EMBO J. 7:2807-2813 (1988)	
dc		Sambrook et al., Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 1989)	
Examiner's Signature	Deborah Croch		Date Considered
			4/26/00

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/149,718
				Filing Date	September 8, 1998
				First Named Inventor	Kate Dora Games, et al.
				Group Art Unit	1643
				Examiner Name	Not yet assigned
Sheet	Page 27	of	34	Attorney Docket Number	ANS 101 CIP(2)

## OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T <sup>2</sup>	
		Sander, M., et al., "The role of the adrenal gland in hypertensive transgenic rat TGR(mREN2)27" Endocrinology 131(2):807-814 (1992) (abstract only)		
		Sandhu, et al., "Expression of the Human -Amyloid Protein of Alzheimer's Disease Specifically in the Brains of Transgenic Mice," The Journal of Biological Chemistry 266(32): 21331-21334 (1991)		
		Saper and German, "Hypothalamic pathology in Alzheimer's disease," Neuro. Letters 74:364-370 (1987)		
		Sasahara, et al., "PDGF B-Chain in Neurons of the Central Nervous System, Posterior Pituitary, and in a Transgenic Model," Cell 64:217-227 (1991)		
		Satlin, et al., "Circadian Temperature and Locomotor Activity Rhythms in Alzheimer's Disease," Neurobiol. Aging 11:337 (1990)		
		Scangos, et al., "Gene Transfer into Mice," Adv. in Genet. 24:285-322 (1987)		
		Schellenberg, et al., "Genetic Linkage Evidence for a Familial Alzheimer's Disease Locus on Chromosome 14," Science 258:668-670 (1992)		
		Schneider, "Biotechnology's Cash Cow," The New York Times Magazine 44 (June 12, 1988)		
		Schilling, et al., "Synthesis and characterization of the Kunitz protease-inhibitor domain of the -amyloid precursor protein," Gene 98:225-230 (1991)		
		Schwagerl, et al., "Elevated Levels of the Endosomal-Lysosomal Proteinase Cathepsin D in Cerebrospinal Fluid in Alzheimer Disease," Journal of Neurochemistry 64:443-446 (1995)		
		Sedlak, "Athena Neurosciences/Eli Lilly & Academic Team Develop Alzheimer's Lab Mouse Model," Genetic Engineering News p. 1 (March 1, 1995)		
Examiner's Signature	Deborah Crutch		Date Considered	4/26/00

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/149,718
				Filing Date	September 8, 1998
				First Named Inventor	Kate Dora Games, et al.
				Group Art Unit	1643
				Examiner Name	Not yet assigned
Sheet	Page 28	of	34	Attorney Docket Number	ANS 101 CIP(2)

## OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T <sup>2</sup>
dc		Selkoe, "Normal and Abnormal Biology of the -Amyloid Precursor Protein," Ann. Rev. Neurosci. 17:489-517 (1994)	
		Selkoe, "In the Beginning. . .", Nature 354:432-433 (1991)	
		Selkoe, "Amyloid Protein and Alzheimer's Disease," Scientific American 265(5):68-76 (1991)	
		Selkoe, "Biochemistry of Altered Brain Proteins in Alzheimer's Disease," Ann. Rev. Neurosci. 12:463-490 (1989)	
		Selkoe D., "Normal and Abnormal Biology of the -Amyloid Precursor Protein" Annu. Rev. Neurosci. 17:489-517 (1994)	
		Selkoe, "Physiological Production of the $\beta$ -Amyloid Protein and the Mechanism of Alzheimer's Disease," Trends in Neuroscience 16:403-409 (1993)	
		Seubert, et al., "Secretion of -amyloid precursor protein cleaved at the amino terminus of the -amyloid peptide," Nature 361:260-263 (1993)	
		Seubert, et al., "Isolation and quantification of soluble Alzheimer's -peptide from biological fluids," Nature 359:325-327 (1992)	
		Shoji, et al., "Production of the Alzheimer Amyloid Protein by Normal Proteolytic Processing," Science 258:126-129 (1992)	
		Shanahan, C., et al., "Regulation of expression of a sheep metallothionein 1a-sheep growth hormone fusion gene in transgenic mice" Mol. Cell. Biol. 9(12):5473-5479 (1989) (abstract only)	
dc		Sims, et al., "Presynaptic Cholinergic Dysfunction in Patients with Dementia," J. Neurochem. 40: 503-509 (1983)	
Examiner's Signature	Deborah Cronch		Date Considered
		4/26/00	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/149,718
				Filing Date	September 8, 1998
				First Named Inventor	Kate Dora Games, et al.
				Group Art Unit	1643
				Examiner Name	Not yet assigned
Sheet	Page 29	of	34	Attorney Docket Number	ANS 101 CIP(2)

## OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T <sup>2</sup>	
		Sims, et al., "Glucose Metabolism and Acetylcholine Synthesis in Relation to Neuronal Activity in Alzheimer's Disease," Lancet 1:333-336 (1980)		
		Sirinathsinghi, "Transgenic Models of Alzheimer's Disease" Current Research In Alzheimer's Disease 3(2): 47-56.		
		Sisodia, et al., "Evidence That -Amyloid Protein in Alzheimer's Disease Is Not Derived by Normal Processing," Science 248:492-495 (1990)		
		Smith, et al., "Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease," Proc. Natl. Acad. Sci. USA 88:10540-10543 (1991)		
		Smith, et al., "Carbonyl-Related Posttranslational Modification of Neurofilament Protein in the Neurofibrillary Pathology of Alzheimer's Disease," J. Neurochemistry 64:2660-2666 (1995)		
		Southern and Berg, "Transformation of Mammalian Cells to Antibiotic Resistance with a Bacterial Gene Under Control of the SV40 Early Region Promoter," J. Mol. Appl. Gen. 1:327-341 (1982)		
		Sparks, D., et al., "Temporal Sequence of Plaque Formation in the Cerebral Cortex of Non-Demented Individuals" J. Neuropathol Exp Neurol 52(2):135-142 (1993)		
		Spencer, et al., "Behavioral Impairments Related to Cognitive Dysfunction in the Autoimmune New Zealand Black Mouse," Behavioral Neuroscience 100(3):353-358 (1986)		
		Spetch, et al., "A program that stimulates random choices in radial arm mazes and similar choice situations" Behavior Research Methods & Instrumentation 12(3):377-378 (1980)		
		St. George-Hyslop, et al., "The Genetic Defect Causing Familial Alzheimer's Disease Maps on Chromosome 21," Science 235:885-890 (1987)		
	St. George-Hyslop, et al., "Absence of Duplication of Chromosome 21 Genes in Familial and Sporadic Alzheimer's Disease," Science 238:664-666 (1987)			
Examiner's Signature	Deborah Chond		Date Considered	4/26/00

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/149,718
		Filing Date	September 8, 1998
		First Named Inventor	Kate Dora Games, et al.
		Group Art Unit	1643
		Examiner Name	Not yet assigned
Sheet	Page 30	of	34
		Attorney Docket Number	ANS 101 CIP(2)

## OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T <sup>2</sup>
dc		St. George-Hyslop, et al., "Genetic evidence for a novel familial Alzheimer's disease locus on chromosome 14," Nature Genetics 2:330-334 (1992)	
		Stanley, et al., "The structure and expression of the murine gene encoding granulocyte-macrophage colony stimulating factor: evidence for utilisation of alternative promoters," EMBO J. 4:2569-2573 (1985)	
		Stopa, et al., "Human suprachiasmatic nuclei in Alzheimer's disease," J. Neuropathol. Exp. Neurol. 48:327 (1989)	
		Su, J., et al., "Early phosphorylation of tau in Alzheimer's disease occurs at Ser-202 and is preferentially located within neurites" Neuroreport 5(17):2358-2362 (1994)	
		Suzuki, et al., "An Increased Percentage of Long Amyloid Protein Secreted by Familial Amyloid Protein Precursor (APP717) Mutants," Science 264:1336-1340 (1994)	
		Swaab, et al., "The Suprachiasmatic Nucleus of the Human Brain in Relation to Sex, Age and Senile Dementia," Brain Res. 342:37-44 (1985)	
		Swanson, M., et al., "High level expression of human apolipoprotein A-I in transgenic rats raises total serum high density lipoprotein cholesterol and lowers rat apolipoprotein A-I" Transgenic Res. 1(3):142-147 (1992) (abstract only)	
		Swanson, et al., "Novel developmental specificity in the nervous system of transgenic animals expressing growth hormone fusion genes," Nature 317:363-366 (1985)	
		Tamaoka, et al., "Identification of a stable fragment of the Alzheimer amyloid precursor containing the -protein in brain microvessels," Proc. Natl. Acad. Sci. U.S.A. 89:1345-1349 (1992)	
		Tanzi, "Clinical Implications of Basic Research: A Promising Animal Model of Alzheimer's Disease," New England J. Med. 332:1512-1513 (1995)	
dc		Tanzi, et al., "The Amyloid Protein Gene is not Duplicated in Brains from Patients with Alzheimer's Disease," Science 238: 666-669 (1987)	
Examiner's Signature	Deborah Cronch		Date Considered
		4/26/00	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/149,718
				Filing Date	September 8, 1998
				First Named Inventor	Kate Dora Games, et al.
				Group Art Unit	1643
				Examiner Name	Not yet assigned
Sheet	Page 31	of	34	Attorney Docket Number	ANS 101 CIP(2)

## OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T <sup>2</sup>
dc		Tanzi, et al., "The Genetic Defect in Familial Alzheimer's Disease is not Tightly Linked to the Amyloid -Protein Gene," Nature 329:156-157 (1987)	
		Tanzi, et al., "Molecular Genetic Approaches to Alzheimer's Disease," Trends in Neuroscience 12(4):152-158 (1989).	
		Tanzi, et al., "Amyloid Protein Gene: cDNA, mRNA Distribution and Genetic Linkage Near the Alzheimer Locus," Science 235:881-884 (1987)	
		Tanzi, et al., "Protease Inhibitor Domain Encoded by an Amyloid Protein Precursor mRNA Associated with Alzheimer's Disease," Nature 331:528-530 (1988)	
		Tate-Ostroff et al., "Identification of Cellular and Extracellular Sites of Amyloid Precursor Protein Extracytoplasmic Domain in Normal and Alzheimer Disease Brains," Proceedings of the National Academy of Science (U.S.A.) 86:745-749 (1989)	
		Thybo, N., et al., "Morphology and function of mesenteric resistance arteries in transgenic rats with low-renin hypertension" J. Hypertens. 10(10):1191-1196 (1992) (abstract only)	
		Tooyama, et al., "Acidic fibroblast growth factor-like immunoreactivity in brain of Alzheimer patients," Neuroscience Letters 121:155-158 (1991)	
		Tooyama, et al., "Immunohistochemical Study of 2 Macroglobulin Receptor in Alzheimer and Control Postmortem Human Brain," Molecular and Chem. Neuropathol. 18:153-160 (1993)	
		Trojanowski, et al., "Altered Tau and Neurofilament Proteins in Neuro-Degenerative Diseases: Diagnostic Implications for Alzheimer's Disease and Leqy Body Dementias," Brain Pathology 3:45-54 (1993)	
		Tsujita, Y., et al., "Hypolipidemic Effects in Dogs of ML-236B, A Competitive Inhibitor of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase" Atherosclerosis 32:307-313 (1979)	
dc		Tsujita, Y., et al., "CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species" Biochim. Biophys. Acta 877:50-60 (1986)	
Examiner's Signature	Deborah Cronch		Date Considered
			4/26/00

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/149,718
		Filing Date	September 8, 1998
		First Named Inventor	Kate Dora Games, et al.
		Group Art Unit	1643
		Examiner Name	Not yet assigned
Sheet	Page 32	of	34
		Attorney Docket Number	ANS 101 CIP(2)

## OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T <sup>2</sup>
dc		Ueda, et al., "Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease," Proc. Natl. Aca. Sci. USA 90:11282-11286 (1993)	
		Van Broeckhaven et al., "Mapping of a gene predisposing to early-onset Alzheimer's disease to chromosome 14q24.3," Nature Genetics 2:335-339 (1992)	
		Van Broeckhoven, et al., "Amyloid Protein Precursor Gene and Hereditary Cerebral Hemorrhage with Amyloidosis (Dutch)," Science 248:1120-1122 (1990)	
		Van Hoesan, et al., Hippocampus 1:1-8 (1991)	
		Velander, W., et al., "High-level expression of a heterologous protein in the milk of transgenic swine using the cDNA encoding human protein C" Proc. Natl. Acad. Sci. USA 89(24):12003-12007 (1992) (abstract only)	
		Vickers, J., et al., "Alterations in Neurofilament Protein Immunoreactivity in Human Hippocampal Neurons Related to Normal Aging and Alzheimer's Disease" Neuroscience 62(1):1-13 (1994)	
		Vincent, et al., "Embryonic expression of a Drosophila src gene: alternate forms of the protein are expressed in segmental stripes and in the nervous system," Genes & Devel. 3:334-347 (1989)	
		Vize, P., et al., "Introduction of a porcine growth hormone fusion gene into transgenic pigs promotes growth" J. Cell. Sci. 90(Pt 2):295-300 (1988) (abstract only)	
		Wall, R., et al., "High-level synthesis of a heterologous milk protein in the mammary glands of transgenic swine" Proc. Natl. Acad. Sci. USA 88(5):1696-1700 (1991) (abstract only)	
		Wang, et al., "Quantitation of mRNA by the polymerase chain reaction," Proc. Natl. Acad. Sci. U.S.A. 86:9717-9721 (1989)	
dc		Weidemann, et al., "Identification, Biogenesis, and Localization of Precursors of Alzheimer's Disease A4 Amyloid Protein," Cell 57:115-126 (1989)	
Examiner's Signature	Deborah Cronch		Date Considered
			11/26/00

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/149,718
				Filing Date	September 8, 1998
				First Named Inventor	Kate Dora Games, et al.
				Group Art Unit	1643
				Examiner Name	Not yet assigned
Sheet	Page 33	of	34	Attorney Docket Number	ANS 101 CIP(2)

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T <sup>2</sup>
de		Weidle, U., et al., "Genes encoding a mouse monoclonal antibody are expressed in transgenic mice, rabbits and pigs" Gene 98(2):185-191 (1991) (abstract only)	
		Wiegart, M., et al., "Production of transgenic pigs harbouring a rat phosphoenolpyruvate carboxykinase-bovine growth hormone fusion gene" J. Reprod. Fertil. Suppl. 41:89-96 (1990) (abstract only)	
		Whitehouse, et al., "Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain," Science 215:1237-1239 (1982)	
		Wirak, et al., "Deposits of Amyloid Protein in the Central Nervous System of Transgenic Mice," Science 253:323-325 (1991)	
		Wirak, et al., "Age-Associated Inclusions in Normal and Transgenic Mouse Brain," Science 255:1443-1445 (1992)	
		Wirak, et al., "Regulatory Region of Human Amyloid Precursor Protein (APP) Gene Promotes Neuron-Specific Gene Expression in the CNS of Transgenic Mice," The EMBO J. 10:289-296 (1991)	
		Wirak, et al., "Regulatory region of human amyloid precursor protein (APP) gene promotes neuron-specific gene expression in the CNS of transgenic mice," The EMBO Journal 10(2):289-296 (1991)	
		Wisniewski, et al. "Alzheimer's Disease and Soluble Aβ," Neurobiology of Aging 15: 143-152 (1994).	
		Witting, et al., "Alterations in the Circadian Rest-Activity Rhythm in Aging and Alzheimer's Disease," Biol. Psychiatry 27:563-572 (1990)	
		Wolozin, et al., "A Neuronal Antigen in the Brains of Alzheimer Patients," Science 232:648 (1986)	
dc		Wood, et al., "Cytokine indices in Alzheimer's temporal cortex: no changes in mature IL-1 or IL-1RA but increases in the associated acute phase proteins IL-6, 2-macroglobulin and C-reactive protein," Brain Research 629:245-252 (1993)	
Examiner's Signature	Deborah Cronch		Date Considered
		4/26/00	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid QMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/149,718
		Filing Date	September 8, 1998
		First Named Inventor	Kate Dora Games, et al.
		Group Art Unit	1643
		Examiner Name	Not yet assigned
Sheet	Page 34	of	34
		Attorney Docket Number	ANS 101 CIP(2)

## OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T <sup>2</sup>	
		Yamaguchi, T., et al., "Zonal distribution and regulation of adrenal renin in a transgenic model of hypertension in the rat" Endocrinology 131(4):1955-1962 (1992) (abstract only)		
		Yamaguchi, et al., "Transgenic mice for the amyloid precursor protein 695 isoform have impaired spatial memory," NeuroReport 2:781-784 (1991)		
		Yamamoto, et al., "Effects of Indeloxazine Hydrochloride on Cognitive Disturbance in Cycloheximide-Treated Mice," Journal of Pharmacy and Pharmacology 41:284-286 (1989)		
		Yankner, et al., "Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease," Science 245:417-420 (1989)		
		Yasuhara, et al., "Midkine, A Novel Neurotrophic Factor, Is Present in Senile Plaques of Alzheimer Disease," Biochem. and Biophys. Res. Comm. 192:246-251 (1993)		
		Yoshikai, et al., "Genomic Organization of the Human Amyloid Beta-Protein Precursor Gene," Gene 102:257-263 (1990)		
		Yoshikai, et al., "Genomic Organization of the Human Amyloid Beta-Protein Precursor Gene," Gene 102:291-292 (1991)		
		Yoshikawa, et al., "Degeneration in vitro of post-mitotic neurons overexpressing the Alzheimer's amyloid protein precursor," Nature 359:64-67 (1992)		
		Zhao, J., et al., "Secretase Processing of the Amyloid Precursor Protein in Transgenic Mice is Efficient in Neurons but Inefficient in Astrocytes" The Journal of Biological Chemistry 271(49):31407-31411 (1996)		
		Zimmer and Gruss, "Production of chimaeric mice containing embryonic stem (ES) cells carrying a homoeobox Hox 1.1 allele mutated by homologous recombination," Nature 338:150-153 (1989)		
		Zornetzer, "Rapid Forgetting in Aged Rats," Behav. Neur. Biol. 36:49-60 (1982) Chemical Industry Institute of Toxicology, 1987 Annual Report		
Examiner's Signature			Date Considered	4/26/00

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.